Esperion Therapeutics, Inc.’s ESPR share price has dipped by 6.66%, which has investors questioning if this is right time to buy.

The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...

Welcome to Zymeworks first-quarter 2025 results conference call and webcast. (Operator Instructions) I would now like to turn the conference over to Shrinal Inamdar, Senior Director of Investor ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...